

Study	I <sup>2</sup>	Odds Ratio (95% CrI)
-------	----------------	----------------------

### Gefitinib vs Almonertinib

4		0.44 (0.21, 0.91)
Pooled (pair-wise)		0.44 (0.070, 2.7)
Indirect (back-calculated)		NA
Pooled (network)		0.44 (0.094, 2.0)

### Lazertinib vs Amivantamab\_Lazertinib


r1		0.23 (0.14, 0.36)
Pooled (pair-wise)		0.22 (0.039, 1.3)
Indirect (back-calculated)		NA
Pooled (network)		0.21 (0.056, 0.80)

### Osimertinib vs Amivantamab\_Lazertinib

r1		0.16 (0.11, 0.23)
Pooled (pair-wise)		0.16 (0.028, 0.90)
Indirect (back-calculated)		NA
Pooled (network)		0.17 (0.045, 0.63)

### Erlotinib vs Chemotherapy

1		6.5e-24 (3.8e-57, 1.1e+10)
22		4.9e+15 (5.1e-08, 4.6e+38)
27		8.7e+13 (2.7e-08, 2.8e+35)
51		3.9 (0.67, 23.)
68		0.69 (0.29, 1.6)
69		9.0e+21 (2.5e-06, 3.2e+49)
71		1.1e-23 (1.7e-58, 7.2e+11)
80		0.16 (0.010, 2.4)
r3		1.2e-23 (9.7e-57, 1.5e+10)
Pooled (pair-wise)	49.7%	0.93 (0.34, 2.5)
Indirect (back-calculated)		0.30 (0.12, 0.75)
Pooled (network)	52.4%	0.51 (0.25, 0.99)



Study  $I^2$

**Erlotinib\_chemotherapy vs Chemotherapy**

71  
Pooled (pair-wise)  
Indirect (back-calculated)  
Pooled (network) 0.0%

**Gefitinib vs Chemotherapy**


13  
73  
75  
76  
77  
Pooled (pair-wise) 59.1%  
Indirect (back-calculated)  
Pooled (network) 35.1%


**Osimertinib vs Chemotherapy**


42  
Pooled (pair-wise)  
Indirect (back-calculated)  
Pooled (network) 0.0%

**Erlotinib vs Dacomitinib**

45  
59  
Pooled (pair-wise) 0.0%  
Indirect (back-calculated)  
Pooled (network) 0.0%







Study  $I^2$

Odds Ratio (95% CrI)

### Erlotinib\_HER3i vs Erlotinib

62			0.49 (0.084, 2.8)
Pooled (pair-wise)			0.49 (0.043, 5.5)
Indirect (back-calculated)			NA
Pooled (network)			0.48 (0.050, 4.4)

### Erlotinib\_HGFi vs Erlotinib


56			0.92 (0.028, 30.)
Pooled (pair-wise)			0.89 (0.025, 54.)
Indirect (back-calculated)			NA
Pooled (network)			0.91 (0.027, 52.)


### Erlotinib\_IGF\_1Ri vs Erlotinib

44			2.8 (1.5, 5.2)
66			2.8e+16 (4.9e-05, 1.6e+37)
9			7.4e+09 (2.0e-08, 2.8e+27)
Pooled (pair-wise)	75.8%		5.7 (1.4, 30.)
Indirect (back-calculated)			NA
Pooled (network)	69.6%		4.9 (1.5, 20.)

### Erlotinib\_METi vs Erlotinib

12			1.4 (0.82, 2.4)
32			0.97 (0.026, 36.)
39			0.51 (0.13, 2.0)
7			1.1 (0.60, 1.9)
79			1.1e-23 (8.6e-57, 1.5e+10)
Pooled (pair-wise)	41.2%		0.82 (0.29, 2.1)
Indirect (back-calculated)			NA
Pooled (network)	31.6%		0.87 (0.36, 2.0)





Study	I <sup>2</sup>	Odds Ratio (95% CrI)
-------	----------------	----------------------

### Gefitinib\_ERi vs Erlotinib

72		5.8 (1.2, 29.)
Pooled (pair-wise)		5.8 (0.58, 59.)
Indirect (back-calculated)		NA
Pooled (network)		4.2 (0.95, 18.)

### Placebo vs Erlotinib

30		1.0 (0.23, 4.5)
46		1.4 (0.82, 2.5)
58		2.1 (0.48, 9.6)
Pooled (pair-wise)	0.0%	1.4 (0.45, 4.7)
Indirect (back-calculated)		0.52 (0.20, 1.4)
Pooled (network)	57.3%	0.78 (0.36, 1.6)

### Rociletinib vs Erlotinib

53		3.7e-23 (2.3e-56, 6.0e+10)
Pooled (pair-wise)	→	1.4e-39 (1.4e-157, 0.0014)
Indirect (back-calculated)		NA
Pooled (network)	←	1.1e-23 (2.3e-73, 0.022)

### antiangio vs Erlotinib

28		4.7 (3.2, 7.0)
37		13. (2.9, 57.)
Pooled (pair-wise)	73.6%	6.7 (1.8, 27.)
Indirect (back-calculated)		9.0 (2.5, 32.)
Pooled (network)	71.4%	7.8 (3.2, 20.)

### Osimertinib vs Gefitinib\_Erlotinib

31		1.6 (0.87, 3.0)
Pooled (pair-wise)		1.6 (0.27, 9.8)
Indirect (back-calculated)		NA
Pooled (network)		1.6 (0.37, 7.1)

0.01                      1                      80



